相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Identification of methyl (5-(6-((4-(methylsulfonyl)piperazin-1-yl)methyl)-4-morpholinopyrrolo[2,1-f][1,2,4]triazin-2-yl)-4-(trifluoromethyl)pyridin-2-yl)carbamate (CYH33) as an orally bioavailable, highly potent, PI3K alpha inhibitor for the treatment of advanced solid tumors
Hao-Yue Xiang et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2021)
Adaptive resistance to PI3Kα-selective inhibitor CYH33 is mediated by genomic and transcriptomic alterations in ESCC cells
Yu-xiang Wang et al.
CELL DEATH & DISEASE (2021)
Integrating Immunotherapy and Targeted Therapy in Cancer Treatment: Mechanistic Insights and Clinical Implications
Johann S. Bergholz et al.
CLINICAL CANCER RESEARCH (2020)
Emerging roles of class I PI3K inhibitors in modulating tumor microenvironment and immunity
Pu Sun et al.
ACTA PHARMACOLOGICA SINICA (2020)
Analyzing One Cell at a TIME: Analysis of Myeloid Cell Contributions in the Tumor Immune Microenvironment
Vitaliy Davidov et al.
FRONTIERS IN IMMUNOLOGY (2020)
Obesity Shapes Metabolism in the Tumor Microenvironment to Suppress Anti-Tumor Immunity
Alison E. Ringel et al.
CELL (2020)
The PI3K-AKT network at the interface of oncogenic signalling and cancer metabolism
Gerta Hoxhaj et al.
NATURE REVIEWS CANCER (2020)
The PI3K p110δ Isoform Inhibitor Idelalisib Preferentially Inhibits Human Regulatory T Cell Function
Stalin Chellappa et al.
JOURNAL OF IMMUNOLOGY (2019)
Challenges for the Clinical Development of PI3K Inhibitors: Strategies to Improve Their Impact in Solid Tumors
Ariella B. Hanker et al.
CANCER DISCOVERY (2019)
Phosphoinositide 3-kinaseδ is a regulatory T-cell target in cancer immunotherapy
Ee Lyn Lim et al.
IMMUNOLOGY (2019)
Comprehensive Integration of Single-Cell Data
Tim Stuart et al.
CELL (2019)
Tumor-intrinsic PIK3CA represses tumor immunogenicity in a model of pancreatic cancer
Nithya Sivaram et al.
JOURNAL OF CLINICAL INVESTIGATION (2019)
PI3K/Akt/mTOR inhibitors in cancer: At the bench and bedside
Ali S. Alzahrani
SEMINARS IN CANCER BIOLOGY (2019)
PI3K alpha inhibitors sensitize esophageal squamous cell carcinoma to radiation by abrogating survival signals in tumor cells and tumor microenvironment
Jia-jie Shi et al.
CANCER LETTERS (2019)
For Better or Worse: The Potential for Dose Limiting the On-Target Toxicity of PI 3-Kinase Inhibitors
Christina M. Buchanan et al.
BIOMOLECULES (2019)
The clinical KRAS(G12C) inhibitor AMG 510 drives anti-tumour immunity
Jude Canon et al.
NATURE (2019)
Simultaneous inhibition of PI3Kα and CDK4/6 synergistically suppresses KRAS-mutated non-small cell lung cancer
Yuxiang Wang et al.
CANCER BIOLOGY & MEDICINE (2019)
CDK4/6 Inhibition Augments Antitumor Immunity by Enhancing T-cell Activation
Jiehui Deng et al.
CANCER DISCOVERY (2018)
Decrease in phosphorylated ERK indicates the therapeutic efficacy of a clinical PI3Kα-selective inhibitor CYH33 in breast cancer
Xue-ling Liu et al.
CANCER LETTERS (2018)
The PI3K Pathway at the Crossroads of Cancer and the Immune System: Strategies for Next Generation Immunotherapy Combinations
Dearbhaile C. Collins et al.
CURRENT CANCER DRUG TARGETS (2018)
FOXP3+Treg as a therapeutic target for promoting anti-tumor immunity
Theresa L. Whiteside
EXPERT OPINION ON THERAPEUTIC TARGETS (2018)
Recombinant Activated Coagulation Factor VII (rFVIIa) for Treatment of the Tracheobronchial Bleeding in Mechanically Ventilated (MV) Thrombocytopenic Patients (pts)
Gennadii M. Galstian et al.
BLOOD (2018)
PI3K Inhibition Reduces Mammary Tumor Growth and Facilitates Antitumor Immunity and Anti-PD1 Responses
Jiqing Sai et al.
CLINICAL CANCER RESEARCH (2017)
Fatty acid synthase (FASN) as a therapeutic target in breast cancer
Javier A. Menendez et al.
EXPERT OPINION ON THERAPEUTIC TARGETS (2017)
CDK4/6 inhibition triggers anti-tumour immunity
Shom Goel et al.
NATURE (2017)
Enhancing CD8+ T Cell Fatty Acid Catabolism within a Metabolically Challenging Tumor Microenvironment Increases the Efficacy of Melanoma Immunotherapy
Ying Zhang et al.
CANCER CELL (2017)
Macrophage Polarization Contributes to Glioblastoma Eradication by Combination Immunovirotherapy and Immune Checkpoint Blockade
Dipongkor Saha et al.
CANCER CELL (2017)
The PI3K Pathway in Human Disease
David A. Fruman et al.
CELL (2017)
First in human study of the first-in-class fatty acid synthase (FASN) inhibitor TVB-2640
Gerald Falchook et al.
CANCER RESEARCH (2017)
PI3Kγ is a molecular switch that controls immune suppression
Megan M. Kaneda et al.
NATURE (2016)
Lipidomics: Techniques, Applications, and Outcomes Related to Biomedical Sciences
Kui Yang et al.
TRENDS IN BIOCHEMICAL SCIENCES (2016)
Oncogenic PIK3CA mutations reprogram glutamine metabolism in colorectal cancer
Yujun Hao et al.
NATURE COMMUNICATIONS (2016)
Macrophage PI3Kγ Drives Pancreatic Ductal Adenocarcinoma Progression
Megan M. Kaneda et al.
CANCER DISCOVERY (2016)
The PI3K-γ inhibitor, IPI-549, increases antitumor immunity by targeting tumor-associated myeloid cells and remodeling the immune-suppressive tumor microenvironment
Matthew Rausch et al.
CANCER IMMUNOLOGY RESEARCH (2016)
Idelalisib: First-in-Class PI3K Delta Inhibitor for the Treatment of Chronic Lymphocytic Leukemia, Small Lymphocytic Leukemia, and Follicular Lymphoma
Qingshan Yang et al.
CLINICAL CANCER RESEARCH (2015)
Short communication: Effect of inhibition of fatty acid synthase on triglyceride accumulation and effect on lipid metabolism genes in goat mammary epithelial cells
J. J. Zhu et al.
JOURNAL OF DAIRY SCIENCE (2015)
What is synergy? The Saariselka agreement revisited
Jing Tang et al.
FRONTIERS IN PHARMACOLOGY (2015)
PI3K in cancer: divergent roles of isoforms, modes of activation and therapeutic targeting
Lauren M. Thorpe et al.
NATURE REVIEWS CANCER (2015)
Systematic combination screening reveals synergism between rapamycin and sunitinib against human lung cancer
Xian Li et al.
CANCER LETTERS (2014)
Inactivation of PI(3)K p110δ breaks regulatory T-cell-mediated immune tolerance to cancer
Khaled Ali et al.
NATURE (2014)
Idelalisib and Rituximab in Relapsed Chronic Lymphocytic Leukemia
Richard R. Furman et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Selective Inhibition of Regulatory T Cells by Targeting the PI3K-Akt Pathway
Rasha Abu-Eid et al.
CANCER IMMUNOLOGY RESEARCH (2014)
GSVA: gene set variation analysis for microarray and RNA-Seq data
Sonja Haenzelmann et al.
BMC BIOINFORMATICS (2013)
Coordinated regulation of myeloid cells by tumours
Dmitry I. Gabrilovich et al.
NATURE REVIEWS IMMUNOLOGY (2012)
Macrophage-Derived AIM Is Endocytosed into Adipocytes and Decreases Lipid Droplets via Inhibition of Fatty Acid Synthase Activity
Jun Kurokawa et al.
CELL METABOLISM (2010)
Genetic analysis of the role of the PI3K-Akt pathway in lipopolysaccharide-induced cytokine and tissue factor gene expression in monocytes/macrophages
James P. Luyendyk et al.
JOURNAL OF IMMUNOLOGY (2008)
IL-2 is essential for TGF-β to convert naive CD4+CD25- cells to CD25+Foxp3+ regulatory T cells and for expansion of these cells
Song Guo Zheng et al.
JOURNAL OF IMMUNOLOGY (2007)
C75 alters central and peripheral gene expression to reduce food intake and increase energy expenditure
YJ Tu et al.
ENDOCRINOLOGY (2005)
The phosphatidylinositol 3-kinase-Akt pathway limits lipopolysaccharide activation of signaling pathways and expression of inflammatory mediators in human monocytic cells
M Guha et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2002)
Free fatty acid-induced inhibition of glucose and insulin-like growth factor I-induced deoxyribonucleic acid synthesis in the pancreatic beta-cell line INS-1
SP Cousin et al.
ENDOCRINOLOGY (2001)
分享论文
